These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19969444)

  • 1. Radioiodine ablation for differentiated thyroid cancer-none, one dose or two?
    Rees GJ
    Clin Oncol (R Coll Radiol); 2010 Mar; 22(2):131-5. PubMed ID: 19969444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should we routinely offer a second admission for radioiodine to patients with high-risk differentiated thyroid cancer?
    Gerrard GE; O'Toole L; Roberts F
    Clin Oncol (R Coll Radiol); 2010 Mar; 22(2):136-9. PubMed ID: 20152708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome after high-dose radioiodine therapy for advanced differentiated thyroid carcinoma in childhood.
    Gao YC; Lu HK
    Endocr Res; 2009; 34(4):121-9. PubMed ID: 19878072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetry and thyroid cancer: the individual dosage of radioiodine.
    Lassmann M; Reiners C; Luster M
    Endocr Relat Cancer; 2010 Sep; 17(3):R161-72. PubMed ID: 20448022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis.
    Cheng W; Ma C; Fu H; Li J; Chen S; Wu S; Wang H
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1353-60. PubMed ID: 23436920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.
    Doi SA; Woodhouse NJ
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):765-73. PubMed ID: 10848882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
    Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.
    Hänscheid H; Lassmann M; Luster M; Kloos RT; Reiners C
    Endocr Relat Cancer; 2009 Dec; 16(4):1283-9. PubMed ID: 19628649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine and radiotherapy in the management of thyroid cancers.
    Simpson WJ
    Otolaryngol Clin North Am; 1990 Jun; 23(3):509-21. PubMed ID: 1694984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of dosimetry in the treatment of differentiated thyroid cancer.
    Lassmann M; Hänscheid H; Verburg FA; Luster M
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):107-15. PubMed ID: 21386785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
    Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
    Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on recent developments in the therapy of differentiated thyroid cancer.
    Middendorp M; Grünwald F
    Semin Nucl Med; 2010 Mar; 40(2):145-52. PubMed ID: 20113682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer.
    Mallick U; Harmer C; Hackshaw A
    Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):325-6. PubMed ID: 18474322
    [No Abstract]   [Full Text] [Related]  

  • 15. Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited.
    Doi SA; Woodhouse NJ; Thalib L; Onitilo A
    Clin Med Res; 2007 Jun; 5(2):87-90. PubMed ID: 17607042
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving use of radioiodine therapy in differentiated thyroid cancer.
    Mayson SE; Yoo DC; Gopalakrishnan G
    Oncology; 2015; 88(4):247-56. PubMed ID: 25503797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.
    Bal C; Padhy AK; Jana S; Pant GS; Basu AK
    Cancer; 1996 Jun; 77(12):2574-80. PubMed ID: 8640708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
    Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
    Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioiodine in the treatment of thyroid cancer.
    Van Nostrand D; Wartofsky L
    Endocrinol Metab Clin North Am; 2007 Sep; 36(3):807-22, vii-viii. PubMed ID: 17673129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.